Genmab A/S (GMAB) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.

Which has stronger earnings and valuation, ALNY or GMAB?

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$1.04B	21.22	-$1.13B	-$8.61	-20.45
Genmab A/S	$2.07B	11.41	$781.91M	$1.00	35.71

Does the MarketBeat Community prefer ALNY or GMAB?

Alnylam Pharmaceuticals received 941 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.08% of users gave Alnylam Pharmaceuticals an outperform vote while only 59.24% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1066 77.08%	Underperform Votes 317 22.92%
Genmab A/S	Outperform Votes 125 59.24%	Underperform Votes 86 40.76%

Does the media favor ALNY or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 7 mentions for Genmab A/S and 6 mentions for Alnylam Pharmaceuticals. Genmab A/S's average media sentiment score of 1.39 beat Alnylam Pharmaceuticals' score of 0.91 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, ALNY or GMAB?

Alnylam Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in ALNY or GMAB?

94.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 6.3% of Genmab A/S shares are held by institutional investors. 1.4% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is ALNY or GMAB more profitable?

Genmab A/S has a net margin of 28.78% compared to Genmab A/S's net margin of -85.95%. Alnylam Pharmaceuticals' return on equity of 16.93% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-85.95%	-1,287.80%	-30.66%
Genmab A/S	28.78%	16.93%	15.11%

Do analysts rate ALNY or GMAB?

Alnylam Pharmaceuticals currently has a consensus price target of $245.52, indicating a potential upside of 41.08%. Genmab A/S has a consensus price target of $756.80, indicating a potential upside of 2,042.09%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Genmab A/S is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.77
Genmab A/S	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.27

Summary

Genmab A/S beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.